EMBO Molecular Medicine (Nov 2020)
Sarcoma treatment in the era of molecular medicine
- Thomas GP Grünewald,
- Marta Alonso,
- Sofia Avnet,
- Ana Banito,
- Stefan Burdach,
- Florencia Cidre‐Aranaz,
- Gemma Di Pompo,
- Martin Distel,
- Heathcliff Dorado‐Garcia,
- Javier Garcia‐Castro,
- Laura González‐González,
- Agamemnon E Grigoriadis,
- Merve Kasan,
- Christian Koelsche,
- Manuela Krumbholz,
- Fernando Lecanda,
- Silvia Lemma,
- Dario L Longo,
- Claudia Madrigal‐Esquivel,
- Álvaro Morales‐Molina,
- Julian Musa,
- Shunya Ohmura,
- Benjamin Ory,
- Miguel Pereira‐Silva,
- Francesca Perut,
- Rene Rodriguez,
- Carolin Seeling,
- Nada Al Shaaili,
- Shabnam Shaabani,
- Kristina Shiavone,
- Snehadri Sinha,
- Eleni M Tomazou,
- Marcel Trautmann,
- Maria Vela,
- Yvonne MH Versleijen‐Jonkers,
- Julia Visgauss,
- Marta Zalacain,
- Sebastian J Schober,
- Andrej Lissat,
- William R English,
- Nicola Baldini,
- Dominique Heymann
Affiliations
- Thomas GP Grünewald
- Max‐Eder Research Group for Pediatric Sarcoma Biology Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Marta Alonso
- Program in Solid Tumors and Biomarkers Foundation for the Applied Medical Research University of Navarra Pamplona Pamplona Spain
- Sofia Avnet
- Orthopedic Pathophysiology and Regenerative Medicine Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- Ana Banito
- Pediatric Soft Tissue Sarcoma Research Group German Cancer Research Center (DKFZ) Heidelberg Germany
- Stefan Burdach
- Department of Pediatrics and Children's Cancer Research Center (CCRC) Technische Universität München Munich Germany
- Florencia Cidre‐Aranaz
- Max‐Eder Research Group for Pediatric Sarcoma Biology Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Gemma Di Pompo
- Orthopedic Pathophysiology and Regenerative Medicine Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- Martin Distel
- Children's Cancer Research Institute Vienna Austria
- Heathcliff Dorado‐Garcia
- Department of Pediatric Oncology/Hematology Charité‐Universitätsmedizin Berlin Berlin Germany
- Javier Garcia‐Castro
- Cellular Biotechnology Unit Instituto de Salud Carlos III Madrid Spain
- Laura González‐González
- Cellular Biotechnology Unit Instituto de Salud Carlos III Madrid Spain
- Agamemnon E Grigoriadis
- Centre for Craniofacial and Regenerative Biology King's College London London UK
- Merve Kasan
- Max‐Eder Research Group for Pediatric Sarcoma Biology Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Christian Koelsche
- Institute of Pathology Heidelberg University Hospital Heidelberg Germany
- Manuela Krumbholz
- Department of Pediatrics University Hospital Erlangen Germany
- Fernando Lecanda
- Division of Oncology Adhesion and Metastasis Laboratory Center for Applied Medical Research University of Navarra Pamplona Spain
- Silvia Lemma
- Orthopedic Pathophysiology and Regenerative Medicine Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- Dario L Longo
- Institute of Biostructures and Bioimaging (IBB) Italian National Research Council (CNR) Turin Italy
- Claudia Madrigal‐Esquivel
- Department of Oncology and Metabolism University of Sheffield Sheffield UK
- Álvaro Morales‐Molina
- Cellular Biotechnology Unit Instituto de Salud Carlos III Madrid Spain
- Julian Musa
- Max‐Eder Research Group for Pediatric Sarcoma Biology Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Shunya Ohmura
- Max‐Eder Research Group for Pediatric Sarcoma Biology Institute of Pathology Faculty of Medicine LMU Munich Munich Germany
- Benjamin Ory
- Université de Nantes, Inserm, U1238 Nantes France
- Miguel Pereira‐Silva
- Department of Pharmaceutical Technology Faculty of Pharmacy University of Coimbra Coimbra Portugal
- Francesca Perut
- Orthopedic Pathophysiology and Regenerative Medicine Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- Rene Rodriguez
- Instituto de Investigación Sanitaria del Principado de Asturias Oviedo Spain
- Carolin Seeling
- Institute of Pathology Ulm University Ulm Germany
- Nada Al Shaaili
- Department of Oncology and Metabolism University of Sheffield Sheffield UK
- Shabnam Shaabani
- Department of Drug Design University of Groningen Groningen The Netherlands
- Kristina Shiavone
- Department of Oncology and Metabolism University of Sheffield Sheffield UK
- Snehadri Sinha
- Department of Oral and Maxillofacial Diseases University of Helsinki Helsinki Finland
- Eleni M Tomazou
- Children's Cancer Research Institute Vienna Austria
- Marcel Trautmann
- Division of Translational Pathology Gerhard‐Domagk‐Institute of Pathology Münster University Hospital Münster Germany
- Maria Vela
- Hospital La Paz Institute for Health Research (IdiPAZ) Madrid Spain
- Yvonne MH Versleijen‐Jonkers
- Department of Medical Oncology Radboud University Medical Center Nijmegen The Netherlands
- Julia Visgauss
- Medical Center Duke University Durham NC USA
- Marta Zalacain
- Institute of Biostructures and Bioimaging (IBB) Italian National Research Council (CNR) Turin Italy
- Sebastian J Schober
- Department of Pediatrics and Children's Cancer Research Center (CCRC) Technische Universität München Munich Germany
- Andrej Lissat
- University Children′s Hospital Zurich – Eleonoren Foundation Kanton Zürich Zürich Switzerland
- William R English
- Department of Oncology and Metabolism University of Sheffield Sheffield UK
- Nicola Baldini
- Orthopedic Pathophysiology and Regenerative Medicine Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- Dominique Heymann
- Department of Oncology and Metabolism University of Sheffield Sheffield UK
- DOI
- https://doi.org/10.15252/emmm.201911131
- Journal volume & issue
-
Vol. 12,
no. 11
pp. n/a – n/a
Abstract
Abstract Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult‐to‐treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
Keywords